메뉴 건너뛰기




Volumn 4, Issue 3, 2003, Pages 187-192

Advances in the use of taxanes in the adjuvant therapy of breast cancer

Author keywords

Anthracyclines; Combination therapy; Docetaxel; Paclitaxel; Sequential therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

EID: 0141502410     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70624-3     Document Type: Review
Times cited : (21)

References (34)
  • 1
    • 0002214177 scopus 로고    scopus 로고
    • Chemotherapy of breast cancer
    • Perry MC, ed. 2nd edition. Baltimore, MD: Williams & Willkins
    • Kardinal CG, Cole JT. Chemotherapy of breast cancer. In: Perry MC, ed. The Chemotherapy Source Book, 2nd edition. Baltimore, MD: Williams & Willkins, 1996:1125-1183.
    • (1996) The Chemotherapy Source Book , pp. 1125-1183
    • Kardinal, C.G.1    Cole, J.T.2
  • 2
    • 0032547564 scopus 로고    scopus 로고
    • Polychemotherapy for early breast cancer: An overview of the randomized trials
    • Early Breast Cancer Trialists Collaborative Group
    • Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists Collaborative Group. Lancet 1998; 352: 930-942.
    • (1998) Lancet , vol.352 , pp. 930-942
  • 3
    • 0032949449 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
    • Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999, 17:1413-1424.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 1413-1424
    • Nabholtz, J.M.1    Senn, H.J.2    Bezwoda, W.R.3
  • 4
    • 17344390083 scopus 로고    scopus 로고
    • Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomized phase III study with crossover on progression by the Scandinavian Breast Group
    • Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194-1201.
    • (1999) Eur. J. Cancer , vol.35 , pp. 1194-1201
    • Sjostrom, J.1    Blomqvist, C.2    Mouridsen, H.3
  • 5
    • 0037132372 scopus 로고    scopus 로고
    • Docetaxel vs 5-fluorouracil plus vinorelbine in metastic breast cancer after anthracycline therapy failure
    • Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87:1210-1215.
    • (2002) Br. J. Cancer , vol.87 , pp. 1210-1215
    • Bonneterre, J.1    Roche, H.2    Monnier, A.3
  • 6
    • 0032787785 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
    • Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341-2354.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 2341-2354
    • Chan, S.1    Friedrichs, K.2    Noel, D.3
  • 7
    • 0033956932 scopus 로고    scopus 로고
    • Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over
    • Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000;18:724-733
    • (2000) J. Clin. Oncol. , vol.18 , pp. 724-733
    • Paridaens, R.1    Biganzoli, L.2    Bruning, P.3
  • 8
    • 0037441856 scopus 로고    scopus 로고
    • Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastic breast cancer: An Intergrop Trial (E1193)
    • Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastic breast cancer: An Intergrop Trial (E1193). J Clin Oncol 2003; 21:588-592.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 588-592
    • Sledge, G.W.1    Neuberg, D.2    Bernardo, P.3
  • 9
    • 0037445247 scopus 로고    scopus 로고
    • Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter phase III trial
    • Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter phase III trial. J Clin Oncol 2003; 21:968-975.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 968-975
    • Nabholtz, J.M.1    Falkson, C.2    Campos, D.3
  • 10
    • 0035868906 scopus 로고    scopus 로고
    • Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
    • Jassem J, Tadeusz P, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-1715.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1707-1715
    • Jassem, J.1    Tadeusz, P.2    Pluzanska, A.3
  • 11
    • 0037099533 scopus 로고    scopus 로고
    • Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first line therapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial
    • Biganzoli L, Cofer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first line therapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20:3114-3121.
    • (2002) J. Clin. Oncol. , vol.20 , pp. 3114-3121
    • Biganzoli, L.1    Cofer, T.2    Bruning, P.3
  • 12
    • 0001413607 scopus 로고    scopus 로고
    • Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study
    • (Abstract #141)
    • Nabholtz JM, Pienkowsi T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21:36a (Abstract #141).
    • (2002) Proc. Am. Soc. Clin. Oncol. , vol.21
    • Nabholtz, J.M.1    Pienkowsi, T.2    Mackey, J.3
  • 13
    • 0037687355 scopus 로고    scopus 로고
    • Randomized trial of dosedense versus conventionally scheduled and sequential versus combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of the Intergroup trial C9741/Cancer and Leukemia Group B trial 9741
    • Citron M, Berry D, Cirrincione C, et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of the Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21:1431-1439
    • (2003) J. Clin. Oncol. , vol.21 , pp. 1431-1439
    • Citron, M.1    Berry, D.2    Cirrincione, C.3
  • 14
    • 0037445132 scopus 로고    scopus 로고
    • Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    • Henderson IC, Berry D, Demetri G, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 976-983
    • Henderson, I.C.1    Berry, D.2    Demetri, G.3
  • 15
    • 0041802362 scopus 로고    scopus 로고
    • Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
    • (Abstract #12)
    • Mamoumas E, Bryant J, Lembersky B, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 2003; 22:4 (Abstract #12).
    • (2003) Proc. Am. Soc. Clin. Oncol. , vol.22 , pp. 4
    • Mamoumas, E.1    Bryant, J.2    Lembersky, B.3
  • 16
    • 0028877036 scopus 로고
    • Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-sequence-finding study
    • Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-sequence-finding study. J Clin Oncol 1995; 13:2688-2699.
    • (1995) J. Clin. Oncol. , vol.13 , pp. 2688-2699
    • Gianni, L.1    Munzone, E.2    Capri, G.3
  • 17
    • 0030977999 scopus 로고    scopus 로고
    • Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
    • Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15:1906-1915.
    • (1997) J. Clin. Oncol. , vol.15 , pp. 1906-1915
    • Gianni, L.1    Vigano, L.2    Locatelli, A.3
  • 18
    • 0025063119 scopus 로고
    • Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumours: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
    • Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumours: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8:1483-1496.
    • (1990) J. Clin. Oncol. , vol.8 , pp. 1483-1496
    • Fisher, B.1    Brown, A.M.2    Dimitrov, N.V.3
  • 19
    • 0031927983 scopus 로고    scopus 로고
    • Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
    • Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998; 16:2651-2658.
    • (1998) J. Clin. Oncol. , vol.16 , pp. 2651-2658
    • Levine, M.N.1    Bramwell, V.H.2    Pritchard, K.I.3
  • 20
    • 84898697122 scopus 로고    scopus 로고
    • Anthracycline versus non-anthracycline based chemotherapy in the adjuvant treatment of breast cancer: A meta-analysis
    • (Abstract #338)
    • Hamm CM, Gertler S, Tomiak E, et al. Anthracycline versus non-anthracycline based chemotherapy in the adjuvant treatment of breast cancer: a meta-analysis. Breast Cancer Res Treat 1998; 50:285 (Abstract #338).
    • (1998) Breast Cancer Res. Treat. , vol.50 , pp. 285
    • Hamm, C.M.1    Gertler, S.2    Tomiak, E.3
  • 21
    • 0030068274 scopus 로고    scopus 로고
    • Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
    • Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 1996; 14:35-45.
    • (1996) J. Clin. Oncol. , vol.14 , pp. 35-45
    • Coombes, R.C.1    Bliss, J.M.2    Wils, J.3
  • 22
    • 0029926323 scopus 로고    scopus 로고
    • Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
    • Misset JL, di Palma M, Delgado M, et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14:1136-1145.
    • (1996) J. Clin. Oncol. , vol.14 , pp. 1136-1145
    • Misset, J.L.1    di Palma, M.2    Delgado, M.3
  • 23
    • 0029839080 scopus 로고    scopus 로고
    • Current status of adjuvant therapy of breast cancer
    • [editorial]
    • Browne V, Buzdar AU, Hortobagyi GN. Current status of adjuvant therapy of breast cancer [editorial]. Cancer J 1996; 9:174-176.
    • (1996) Cancer J. , vol.9 , pp. 174-176
    • Browne, V.1    Buzdar, A.U.2    Hortobagyi, G.N.3
  • 24
    • 0002549155 scopus 로고
    • Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer
    • (Abstract #68)
    • Carpenter JT, Velez-Garcia E, Aron BS, et al. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer. Proc Am Soc Clin Oncol 1994; 13:66 (Abstract #68).
    • (1994) Proc. Am. Soc. Clin. Oncol. , vol.13 , pp. 66
    • Carpenter, J.T.1    Velez-Garcia, E.2    Aron, B.S.3
  • 25
    • 0002890387 scopus 로고    scopus 로고
    • CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup Trial Int 0102
    • (Abstract #2)
    • Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial Int 0102. Proc Am Soc Clin Oncol 1998; 17:1a (Abstract #2).
    • (1998) Proc. Am. Soc. Clin. Oncol. , vol.17
    • Hutchins, L.1    Green, S.2    Ravdin, P.3
  • 26
    • 8944245005 scopus 로고    scopus 로고
    • Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
    • Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14:1858-1867.
    • (1996) J. Clin. Oncol. , vol.14 , pp. 1858-1867
    • Nabholtz, J.M.1    Gelmon, K.2    Bontenbal, M.3
  • 27
    • 0032751111 scopus 로고    scopus 로고
    • Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project project protocol B-26
    • Smith R, Brown A, Mamounas E, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National surgical adjuvant breast and bowel project project protocol B-26. J Clin Oncol 1999; 17:3403-3411.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 3403-3411
    • Smith, R.1    Brown, A.2    Mamounas, E.3
  • 28
    • 0003268462 scopus 로고    scopus 로고
    • Weekly paclitaxel (P) followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3 week (Q 3 wk) P therapy followed by FAC-final results of a prospective phase III randomized trial
    • (Abstract #135)
    • Green M, Buzdar A, Smith T, et al. Weekly paclitaxel (P) followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3 week (Q 3 wk) P therapy followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21:35a (Abstract #135).
    • (2002) Proc. Am. Soc. Clin. Oncol. , vol.21
    • Green, M.1    Buzdar, A.2    Smith, T.3
  • 29
    • 0001261992 scopus 로고    scopus 로고
    • Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342
    • (Abstract #388)
    • Winer E, Berry D, Duggan D, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342. Proc Am Soc Clin Oncol 1998; 17:101a (Abstract #388).
    • (1998) Proc. Am. Soc. Clin. Oncol. , vol.17
    • Winer, E.1    Berry, D.2    Duggan, D.3
  • 30
    • 0003203826 scopus 로고    scopus 로고
    • Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814)
    • (Abstract #143)
    • Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002: 21:37a (Abstract #143).
    • (2002) Proc. Am. Soc. Clin. Oncol. , vol.21
    • Albain, K.S.1    Green, S.J.2    Ravdin, P.M.3
  • 31
    • 0030913595 scopus 로고    scopus 로고
    • Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
    • Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15:1858-1869.
    • (1997) J. Clin. Oncol. , vol.15 , pp. 1858-1869
    • Fisher, B.1    Anderson, S.2    Wickerham, D.L.3
  • 32
    • 0032730426 scopus 로고    scopus 로고
    • Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from the national surgical adjuvant breast and bowel project B-25
    • Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from the national surgical adjuvant breast and bowel project B-25. J Clin Oncol 1999; 17:3374-3388.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 3374-3388
    • Fisher, B.1    Anderson, S.2    DeCillis, A.3
  • 33
    • 0036225444 scopus 로고    scopus 로고
    • Continuous low-dose antiangiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic
    • Kerbel RS, Klement G, Pritchard KL, et al. Continuous low-dose antiangiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 2:12-15.
    • (2002) Ann. Oncol. , vol.2 , pp. 12-15
    • Kerbel, R.S.1    Klement, G.2    Pritchard, K.L.3
  • 34
    • 0035214416 scopus 로고    scopus 로고
    • Metronomic scheduling: The future of chemotherapy?
    • Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2:733-740.
    • (2001) Lancet Oncol. , vol.2 , pp. 733-740
    • Gasparini, G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.